Al-Sawaf O et al. Tislelizumab plus zanubrutinib in patients with Richter transformation: Primary endpoint analysis of the prospective, multi-center, phase-II RT1 trial of the German CLL Study Group. ASH 2023;Abstract 204.
Allan JN et al. Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG). ASH 2023;Abstract 3285.
Brown JR et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). ASH 2023;Abstract 202.
Fürstenau M et al. First-line venetoclax combinations in fit patients with CLL: 4-Year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial. ASH 2023;Abstract 635.
Furstenau M et al. Long-term remissions with MRD-guided acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Follow-up efficacy and circulating tumor DNA analysis of the CLL2-Baag trial. ASH 2023;Abstract 203.
Ghia P et al. Relapse after first-line fixed duration ibrutinib + venetoclax: High response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 CAPTIVATE study. ASH 2023;Abstract 633.
Hillmen P et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the phase III UK NCRI FLAIR study. ASH 2023;Abstract 631.
Moreno C et al. First-line fixed-duration ibrutinib plus venetoclax (ibr+ven) versus chlorambucil plus obinutuzumab (clb+o): 55-month follow-up from the Glow study. ASH 2023;Abstract 634.
Papp E et al. Undetectable MRD status in patients with R/R CLL/SLL with stable disease after lisocabtagene maraleucel treatment: Exploratory analysis of the TRANSCEND CLL 004 Study. ASH 2023;Abstract 3263.
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. ASH 2023;Abstract 636.
Sharman JP et al. Analysis of ventricular arrhythmias and sudden death with acalabrutinib from 5 prospective clinical trials. ASH 2023;Abstract 4643.
Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of Transcend CLL 004. ASH 2023;Abstract 330.
Tam CS et al. Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): Data from an ongoing phase 1/2 study. ASH 2023;Abstract 327.
Wiestner A et al. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. ASH 2023;Abstract 201.
Woyach JA et al. Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton’s tyrosine kinase. ASH 2023;Abstract 328.
Woyach JA et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023;Abstract 325.
Xu L et al. Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p). ASH 2023;Abstract 1902.